ASPRUZYO Drug Patent Profile
✉ Email this page to a colleague
When do Aspruzyo patents expire, and when can generic versions of Aspruzyo launch?
Aspruzyo is a drug marketed by Spil and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in ASPRUZYO is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aspruzyo
A generic version of ASPRUZYO was approved as ranolazine by CHARTWELL RX on July 29th, 2013.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ASPRUZYO?
- What are the global sales for ASPRUZYO?
- What is Average Wholesale Price for ASPRUZYO?
Summary for ASPRUZYO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for ASPRUZYO |
| DailyMed Link: | ASPRUZYO at DailyMed |
US Patents and Regulatory Information for ASPRUZYO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 11,510,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-001 | Feb 28, 2022 | DISCN | Yes | No | 11,510,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 12,161,761 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 10,898,444 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
